This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruotolo, G. Articles by Hamsten, A. Search for Related Content PubMed PubMed Citation Articles by Ruotolo, G. Articles by Hamsten, A.

Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment

Giacomo Ruotolo, MD, PhD^*, Peter Båvenholm, MD, PhD, Kerstin Brismar, MD, PhD, Suad Eféndic, MD, PhD, Carl-G.öran Ericsson, MD, PhD, Ulf de Faire, MD, PhD, Jan Nilsson, MD, PhD^* and Anders Hamsten, MD, PhD^*

^* Atherosclerosis Research Unit, King Gustaf V Research Institute, Stockholm, Sweden
Department of Emergency and Cardiovascular Medicine, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden
Department of Endocrinology and Diabetology, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden
Department of Medicine, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden

View larger version (10K): [in a new window]   Figure 1 Serum IGF-I (upper panel) and IGFBP-1 (lower panel) levels at baseline and at two and five years after randomization in the two study groups (circles = placebo group; squares = bezafibrate group). Data are presented as the least squares mean value ± SEM. Data were analyzed by two-way repeated measures analysis of variance (IGF-I: group p = 0.03, time p = 0.01, interaction p = 0.18; IGFBP-1: group p = 0.0005, time p = 0.91, interaction p = 0.90). *p < 0.05, **p < 0.01 between the two study groups (post-hoc Tukey-Kramer test).

View larger version (32K): [in a new window]   Figure 2 Serum IGF-I levels according to tertiles of angiographic outcome measurements in all participants. Data are presented as the least squares mean value ± SEM. Data were analyzed by analysis of variance (MLD p = 0.05; MSD p = 0.02; % diameter stenosis p = 0.38). *p < 0.05 vs. either low or medium tertile groups (post-hoc Tukey-Kramer test).